We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Eurofins Technologies

Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test k... read more Featured Products: More products

Download Mobile App

Eurofins Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A/B, and RSV A/B

By LabMedica International staff writers
Posted on 02 Dec 2021
Print article
Image: Mplex RT-PCR Respiratory Panel (Photo courtesy of Eurofins Technologies)
Image: Mplex RT-PCR Respiratory Panel (Photo courtesy of Eurofins Technologies)

Eurofins Technologies (Luxembourg) has launched two RT-PCR assays to accurately diagnose respiratory diseases caused by SARS-CoV-2, Influenza virus or RSV. Since initial symptoms produced by these pathogens are indistinguishable, access to accurate and reliable tests will help clinicians improve patient care.

These new CE-marked multiplex kits have been specifically designed to detect and differentiate three viral infections in the same PCR run. The Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR assay facilitates differentiation, in a single reaction, between Influenza A, B, and SARS-CoV-2, with simultaneous detection of two SARS-CoV-2 targets (N-gene + RdRP gene) as recommended by the WHO. The RSV A, RSV B RT-PCR assay can differentiate between respiratory syncytial virus A and B.

Both kits can be processed in parallel on the same plate, using the same temperature profile, and provide results in approximately one hour. An internal control (RNaseP) is included for adequate sample processing, and to monitor RNA extraction and the presence of potential inhibitors in the RT-PCR reaction. The AriaDx and AriaMx thermocyclers from Agilent Technologies are validated for both assays. ABI Prism 7500 Fast SDS and QuantStudio 5 from Applied Biosystems, CFX96 Touch from Bio-Rad, and LightCycler 480 II from Roche are validated for the RSV A, RSV B RT-PCR kit.

Related Links:
Eurofins Technologies

Gold Supplier
Molecular Diagnostic System
Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)
Coagulation Analyzer
DIAcheck C1
Portable Tube Luminometer
Junior LB 9509

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more


view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.